- 9 Bousser MG, Schwège E, Haguenau M, *et al*. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. *Stroke* 1983;14:5-14.
- 10 European Stroke Prevention Study Group. ESPS: principal end points. *Lancet* 1987;ii:1351-4.
- 11 Britton M, Helmers C, Samuelsson K. High dose acetylsalicylic acid after cerebral infarction: a Swedish co-operative study. *Stroke* 1987;18:325-34.
- 12 UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. *J Neurol Neurosurg Psychiatry* 1991;54:1044-54.
- 13 The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg *v* 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. *N Engl J Med* 1991;325:1261-6.
- 14 The SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. *Lancet* 1991;338:1345-9.
- 15 Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. *BMJ* 1988;296:320-31.
- 16 Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet treatment. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ* 1994;308:81-106.
- 17 Candelise L, Landi G, Perrone P, *et al*. A randomized trial of aspirin and sulfinpyrazone in patients with TIA. *Stroke* 1982;13:175-9.
- 18 Matias-Guiu J, Davalos A, Pico M, *et al*. Low dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks. *Acta Neurol Scand* 1987;76:413-21.
- 19 Gent M, Blakely JA, Easton JD, *et al*. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. *Lancet* 1989;i:1215-20.
- 20 Hass WK, Easton JD, Adams HP Jr, *et al*. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. *N Engl J Med* 1989;321:501-7.
- 21 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet* 1996;348:1329-39.
- 22 Diener HC, Cunha L, Forbes C, *et al*. European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci* 1996;143:1-13.
- 23 Caplan LR. Are terms such as completed stroke, or RIND of continued usefulness? *Stroke* 1983;14:431-3.
- 24 Caplan LR. TIAs: we need to return to the question, "What is wrong with Mr Jones?" *Neurology* 1988;38:791-3.
- 25 Feldmann E, Daneault N, Kwan E, *et al*. Chinese-white differences in the distribution of occlusive cerebrovascular disease. *Neurology* 1990;40:1541-5.
- 26 Huang YN, Gao S, Li SW, *et al*. Vascular lesions in Chinese patients with transient ischemic attacks. *Neurology* 1997;48:524-5.
- 27 Caplan LR, Babikian V, Helgason C, *et al*. Occlusive disease of the middle cerebral artery. *Neurology* 1985;35:975-82.
- 28 Lhermitte F, Gautier JC, Derouesne C. Nature of occlusion of the middle cerebral artery. *Neurology* 1970;20:82-8.
- 29 Bogousslavsky J, Barnett HJM, Fox AJ, *et al* for the EC/IC bypass Study Group. Atherosclerotic disease of the middle cerebral artery. *Stroke* 1986;17:1112-20.
- 30 Naritomi H, Sawada T, Kuriyama Y, *et al*. Effect of chronic middle cerebral artery stenosis on the local cerebral hemodynamics. *Stroke* 1985;16:214-19.
- 31 Saito I, Segawa H, Shiokawa Y, *et al*. Middle cerebral artery occlusion: correlation of computed tomography and angiography with clinical outcome. *Stroke* 1987;18:863-8.
- 32 Hinton R, Mohr JP, Ackerman R, *et al*. Symptomatic middle cerebral artery stenosis. *Ann Neurol* 1979;5:152-7.
- 33 Corston RN, Kendall BE, Marshall J. Prognosis in middle cerebral artery stenosis. *Stroke* 1984;15:237-41.
- 34 Moulin DE, Lo R, Chiang J, *et al*. Prognosis in middle cerebral artery occlusion. *Stroke* 1985;16:282-4.
- 35 Feldmeyer JJ, Merendaz C, Regli F. Stenosis symptomatiques de l'artère cérébrale moyenne. *Rev Neurol* 1983;139:725-36.
- 36 Garde A, Samuelsson K, Fahlgren H, *et al*. Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation. *Stroke* 1983;14:677-81.
- 37 Chimowitz MI, Kokkinos J, Strong J, *et al*. The warfarin-aspirin symptomatic intracranial disease study. *Neurology* 1995;45:1488-93.
- 38 Higashida RT, Halbach W, Tsai FY, *et al*. Interventional neurovascular technique for cerebral revascularization in the treatment of stroke. *AJR Am J Roentgenol* 1994;163:793-800.
- 39 Clark WM, Barnwell SL, Young LM, *et al*. Safety and efficacy of angioplasty for intracranial atherosclerotic stenosis [abstract]. *Stroke* 1994;25:273.
- 40 Takis C, Kwan E, Pessin MS, *et al*. Intracranial angioplasty, experience and complications. *AJNR Am J Neuroradiol* 1997;18:1661-8.
- 41 Nakano S, Yokogami K, Ohta H, *et al*. Direct percutaneous transluminal angioplasty for acute middle cerebral artery occlusion. *AJNR Am J Neuroradiol* 1998;19:767-72.
- 42 Suh DC, Sung K-B, Cho YS, *et al*. Transluminal angioplasty for middle cerebral artery stenosis in patients with acute ischemic stroke. *AJNR Am J Neuroradiol* 1999;20:553-8.
- 43 Relman A. What have we learned about the treatment of idiopathic membranous nephropathy with steroids. *N Engl J Med* 1989;320:248-9.
- 44 Alves WA, Macciocchi SN. Ethical considerations in clinical neuroscience. Current concepts in neuroclinical trials. *Stroke* 1996;27:1903-9.
- 45 Angell M. The ethics of clinical research in the third world. *N Engl J Med* 1997;337:847-9.
- 46 Varmus H, Satcher D. Ethical complexities of conducting research in developing countries. *N Engl J Med* 1997;337:1003-5.
- 47 Thibault GE. Clinical problem solving: too old for what? *N Engl J Med* 1993;328:946-50.
- 48 Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. *Ann Intern Med* 1997;126:376-80.
- 49 Mulrow CD, Cook DJ, Davidoff F. Systematic reviews: critical links in the great chain of evidence. *Ann Intern Med* 1997;126:389-91.
- 50 LeLorier J, Gregoire G, Benhaddad A, *et al*. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. *N Engl J Med* 1997;337:536-42.

EDITORIAL COMMENTARIES

Getting to the heart of dementia

The two commonest causes of dementia are probably dementia of the Alzheimer type (DAT) and dementia with Lewy bodies (DLB), and although their pathology is relatively well characterised (albeit controversial in terms of diagnostic features) the clinical expression of these disorders can sometimes be difficult to distinguish. Typically DAT presents with deficits in episodic memory with language involvement whereas in DLB it is more hallucinations with a fluctuating dementia in the context of a parkinsonian syndrome. Distinguishing these two disorders, however, is not always straightforward and in this issue (pp 583-588) Yoshito *et al*¹ claim that such a distinction can be made using, rather surprisingly, a peripheral marker of sympathetic activity—¹²³I] MIBG myocardial scintigraphy.

MIBG is a physiological analogue of noradrenaline (norepinephrine) and is used to label sympathetic postganglionic nerve terminals and so has been most extensively used for diseases targeting the autonomic nervous system, including a range of parkinsonian plus

disorders.^{2,3} Yoshida *et al* now report that myocardial [¹²³I] MIBG is significantly reduced in patients with DLB irrespective of duration of disease or degree of autonomic failure, a situation that is not seen in DAT even when a degree of autonomic failure is documented. This therefore suggests that in both conditions there may be involvement of central autonomic pathways but that in DLB there is additional pathology involving peripheral sympathetic processes; an involvement that is not related to medication.

It is now established that some extrapyramidal diseases have pathology that can involve both the central and peripheral autonomic nervous system (see for example, Stoddard *et al*⁴). However, DLB has not consistently been shown to have any such pathology but this study clearly suggests that this is likely, although it produces no postmortem data to confirm the fact. Indeed the study would be greatly strengthened if the MIBG abnormalities could be correlated with a specific pathological process and the absence of postmortem confirmation of disease in the

two patient groups also limits interpretation. The recruitment of consecutive patients, with its inherent variability, can be seen as a strength of the study, but it also creates problems due to the range of disease seen—for example, patients' mini mental state examination scores ranged from 4 to 26. It is therefore not clear how confident one can be about the positive findings irrespective of disease duration or severity given the few patients at each data point. Indeed it could be argued that comparing only mildly affected patients may be more useful as it is this group that represent the greatest challenge both diagnostically and therapeutically—although the absence of effective long term therapies may even limit this potential at the present time.

In conclusion, this study highlights the possibility that neurodegenerative disorders targeting the cerebral cortex may be distinguished through their effects on sympathetic nerve endings in the heart. However, perhaps the most

important message from this study is to highlight once more that neurodegenerative disorders display widespread pathology and that this needs to be accommodated in any theory of pathogenesis as well as novel therapeutic approaches.

R A BARKER

*Department of Neurology and Cambridge Centre for Brain Repair, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK
rab46@cus.cam.ac.uk*

- 1 Yoshita M, Taki J, Yamada M. A clinical role for ¹²³I MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's type and dementia with lewy bodies. *J Neurol Neurosurg Psychiatry* 2001;71:583–8.
- 2 Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123-metaiodobenzylguanidine myocardial scintigraphy. *J Neurol Sci* 1998;155:60–7.
- 3 Druschky A, Hilz MJ, Platsch G, *et al*. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. *J Neurol Sci* 2000;175:3–12.
- 4 Stoddard SL, Ahlskog JE, Kelly PJ *et al*. Decreased adrenal medullary catecholamines in adrenal transplanted parkinsonian patients compared to nephrectomy patients. *Exp Neurol* 1989;104:218–22.

Videodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy

In the paper by Sakakibara *et al* (this volume, pp 600–606),¹ the differences in findings of investigations of bladder function between patients with Parkinson's disease and multiple system atrophy are reported. The authors' new findings focus on the urethral sphincter mechanism, examining this functionally (using some of the newer urodynamic indices) and fluoroscopically. But the paper also provides a useful summary, reviewing as it does, previous work in this area, which has so far been mainly published in the urological literature. Although urinary symptoms can be troublesome in advanced Parkinson's disease they do not have the same prominence and severity as those seen in early multiple system atrophy, probably due to the multiple defects of neurological control of the bladder and sphincter function that develop in the initial stages of multiple system atrophy. Abnormalities of urethral sphincter innervation, both the external (striated) and intrinsic (bladder neck) are marked as

a feature of multiple system atrophy but not Parkinson's disease, as has been shown in this study.

There has been a tendency up to now to include bladder symptoms as part of the "autonomic failure" which characterises multiple system atrophy, but the growing realisation that the entire system of neurological control of the bladder is selectively involved in its early stages, may lead to a new approach in understanding the evolution of this progressive and fatal neurodegenerative disease.

C J FOWLER

*Department of Uro-Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
c.fowler@ion.ucl.ac.uk*

- 1 Sakakibara R, Hattori T, Uchiyama T, *et al*. Videodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. *J Neurol Neurosurg Psychiatry* 2001;71:600–6.

Sphincter EMG in possible multiple system atrophy: to do or not to do?

In multiple system atrophy (MSA) the motor neurons of sphincter muscles (Onuf's nucleus) degenerate earlier than those of limb muscles (Sung *et al*¹). Such lower motor neuron loss is, in principle, accompanied by muscle pathology, which may be readily assessed by EMG methods, of which there are several. Although there is no doubt that expertise may be accumulated with any of the various methods, data comparing different techniques are only beginning to

appear. Gilad *et al* (this issue, pp 596–99) report on results obtained by concentric needle EMG (CNEMG) single fibre EMG (SFEMG), and interference pattern (IP) analysis in a small group of patients with MSA.² Their findings both confirm and contradict the commonly held views on sphincter EMG findings in MSA. As expected, some EMG abnormalities were found in all patients studied, but the reported changes in isolation (reduced